HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

2012355 citationsJournal Article

Authors

Good health and well-being

Published in: Ophthalmology

Volume 119, Issue 6, pp. 1175-1183

Field-Weighted Citation Impact: 28.33